Who is sponsoring NCT00275197?

NCT00275197 is sponsored by Pfizer.

What condition does NCT00275197 study?

NCT00275197 studies Depressive Disorder, Major.

What drugs are being tested in NCT00275197?

Interventions: Sertraline and Elzasonan Combination, Sertraline, Placebo.

What is the status of NCT00275197?

NCT00275197 is currently COMPLETED.

Last reviewed 2008-10-30 · How we verify

An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder

NCT00275197 Phase 2 COMPLETED

The major purpose of the study is to help determine whether giving the combination of Elzasonan with Zoloft to people with depression is a better treatment than taking Zoloft alone. This study will also compare the safety and tolerability of Elzasonan and Zoloft combination to Zoloft alone or placebo.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	262
Start date	2005-12
Completion	2007-07

Conditions

Depressive Disorder, Major

Interventions

Sertraline and Elzasonan Combination
Sertraline
Placebo

Primary outcomes

The estimated treatment difference (elzasonan plus sertraline - sertraline monotherapy) in MADRS (Montgomery-Asberg Depression Rating Scale) remission rates at Week 8 in patients with MDD.

Countries

United States, Chile, Estonia, Russia